Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003006425 | SCV003309562 | uncertain significance | not provided | 2025-01-11 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 1336 of the COL4A1 protein (p.Val1336Ile). This variant is present in population databases (rs202209298, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with COL4A1-related conditions. ClinVar contains an entry for this variant (Variation ID: 2097707). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt COL4A1 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003006426 | SCV003545125 | uncertain significance | Inborn genetic diseases | 2021-12-16 | criteria provided, single submitter | clinical testing | The c.4006G>A (p.V1336I) alteration is located in exon 45 (coding exon 45) of the COL4A1 gene. This alteration results from a G to A substitution at nucleotide position 4006, causing the valine (V) at amino acid position 1336 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003006425 | SCV003828147 | uncertain significance | not provided | 2021-04-19 | criteria provided, single submitter | clinical testing | |
Ce |
RCV003006425 | SCV004701422 | likely benign | not provided | 2024-08-01 | criteria provided, single submitter | clinical testing | COL4A1: BP4 |
Fulgent Genetics, |
RCV005002925 | SCV005632865 | likely benign | Autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome; Brain small vessel disease 1 with or without ocular anomalies; Hemorrhage, intracerebral, susceptibility to; Retinal arterial tortuosity; Microangiopathy and leukoencephalopathy, pontine, autosomal dominant | 2024-03-21 | criteria provided, single submitter | clinical testing |